

GLOSSARY

A list of all abbreviations and terms appearing in this issue of *Therapy*

α1-AR	α1-adrenergic receptor		Endarterectomy versus Stent Trial	colony-stimulating factor
AAU	Acute anterior uveitis		GN	Glomerulonephritis
AE	Adverse event	CRP	Inflammatory parameters such as C-reactive protein	Gonadotropin releasing hormone
AFO	Ankle-foot orthosis			
AG	Acacia gum supplementation	CsA CsA-ME	Cyclosporin A Cyclosporin A microemulsion	Global Initiative for Chronic Obstructive Lung Disease Gastrointestinal Symptoms Rating Scale
AIPC	Androgen-independent prostate cancer	CTP-37	Carboxy terminal 37 amino acids	GU
ANA	Antinuclear antibodies			Gastric ulcer
ARE	Acute rejection episode	CV	Coefficients of variation	H2
ARR	Absolute risk reduction	CYP	Cytochrome P	H2RA
AS	Ankylosing spondylitis	DA	Dopamine	histamine-2 receptor antagonist
ASAS	Ankylosing Spondylitis Assessment Study	DC	Dendritic cell	Hemodialysis
ASSERT	Stratified Sickle Event Randomized Trial	DGf DMARD	Delayed graft function Disease-modifying, antirheumatic drug	Human leukocyte antigen Health-related quality of life
AUA	American Urological Association	DNP DTH	Dinitrophenyl Delayed-type hypersensitivity	HSP
AUC	Area under the curve			Heat-shock protein
AVM	Arterio-venous malformation	DV EC	Observed concentrations Enteric coated	Herpes simplex virus
b.i.d	Twice daily	ECG	Electrocardiogram	Arthritis associated with inflammatory bowel disease
BASDAI	Bath AS Disease Activity Index	EC-MPS	Enteric-coated mycophenolate sodium	International Classification of Functioning, Disability and Health
BASF1	Bath AS Functional Index	MMF	Mycophenolate mofetil	Inhaled corticosteroid
BASMI	Bath AS Metrology Index	EEG	Electroencephalography	Insulin dependent diabetes mellitus
BBB	Blood-brain barrier	EMEA	European agency for the evaluation of medicinal products	
BHT	Banxia Houpo Tang			Intraoperative floppy iris syndrome
BPA	Biopsy-proven acute rejection	EpCAM	epithelial cell adhesion molecule	Interferon
BPAR	Biopsy-proven acute rejection	ESR	Erythrocyte sedimentation rate	Interleukin
BPH	Benign prostatic hyperplasia			Inosine monophosphate dehydrogenase
BTXA	Botulinum toxin A	ESRF	End stage renal failure	Individual model-predicted concentrations
C2	2-h post-dose CsA level	ESSG	European Spondylarthropathy Study Group	International Prostate Symptom Score
CADASIL	Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy	FES	Functional Electrical Stimulation	International Subarachnoid Aneurysm Trial
CAVATAS	Carotid and Vertebral Artery Transluminal Angioplasty Study	FEV1 FIM	Forced expiratory volume in 1 sec Functional Independence Measure	International Society for the Biological Treatment of Cancer
CEA	Carcinoembryonic antigen			Intention-to-treat
CI	Confidence interval	FO	First order	Individual weight residue
CIMT	Constraint-Induced Movement Therapy	FOCEI	First order conditional estimation with interaction	Absorption rate constant
CL/F	Clearance rate	FPIA	Fluorescence polarization	FO absorption rate constant
CL/F	Interindividual variability on clearance	FVC	immunoassay	Long-acting 2 agonist
Cmax	Maximum plasma concentration	G17 GABA	Forced vital capacity Hormone gastrin 17 γ-aminobutyric acid	LatAm L-BLP25 LES LPD
CNI	Calcineurin inhibitors	GERD	Gastroesophageal reflux disease	LTP LUTS
COPD	Chronic obstructive pulmonary disease	GFR	Glomerular filtration rate	Low protein diet
COX	Cyclooxygenase	GI	Gastrointestinal	Long-term potentiation
CPG	Central pattern generators	GIB	Gastrointestinal bleeding	Lower esophageal sphincter
CrCL	Creatinine clearance	GIQLI	GI Quality of Life Index	Lower urinary tract symptoms
CREST	Carotid Revascularization	GM-CSF	Granulocyte-macrophage	Gastric mucosal associated with lymphoid tissue
			me	Mean predictive error
			ME	Microemulsion

GLOSSARY

A list of all abbreviations and terms appearing in this issue of *Therapy*

MHC-I	Major histocompatibility complex	PGWB	Psychological General WellBeing Index	SP	Substance P
MMF	Mycophenolate mofetil	PK	Pharmacokinetic	SPACE	Symptom Prevention by Acid Control with
MOFV	Minimum objective function value	PP	Per protocol		Esomeprazole
MPA	Mycophenolic acid	PPI	Proton pump inhibitor	SpAs	Spondyloarthritides
MPAG	Mycophenolic acid glucuronide	PRED	Population model-predicted concentration	SR	Slow-release
MPL	Monophosphoryl lipid A	PSA	Prostate-specific antigen	STn	Sialyl Tn
MR	Modified release	PsA	Psoriatic arthritis	TDM	Therapeutic drug monitoring
MRI	Magnetic resonance imaging	Qmax	Maximum urinary flow	TENS	Transcutaneous electrical nerve stimulation
MRSA	Methicillin-resistant <i>Staphylococcus aureus</i>	QoL	Quality of life	TES	Therapeutic Electrical Stimulation
MUC-1	Mucin -1	RA	Rheumatoid arthritis	TIA	Transient Ischaemic Attack
myPROMS	Myfortic PROspective Multicenter Study	RCT	Randomised controlled trial	tmax	Maximum concentration
NASA	Nexium Anti-inflammatory Symptom Amelioration	REM	Reactive arthritis	TNF	Tumor necrosis factor
NNT	Number needed to treat	rmse	Rapid eye movement	tPA	Tissue plasminogen activator
NSAIDs	Nonsteroidal anti-inflammatory drugs	RR	Root mean squared prediction error	TTP	Thrombotic
NSCLC	Non small-cell lung cancer	RRT	Relative risk	UBT	thrombocytopenic purpura
OAB	Overactive bladder	SCS	Dialysis and transplantation	USPA	Urea breath test
OCAS	Oral controlled absorption system	SD	Symptom Composite Score	Undifferentiated	spondyloarthropathy
PAP	Prostatic acid phosphatase	SE	Standard deviation	USRDS	US Renal Data System
PBWS	Partial body weight support	V/F	Standard error;	UUI	Urge urinary incontinence
PDE	Phosphodiesterase	SGRQt	Volume of distribution	V/F	Volume of distribution
PFO	Patent foramen ovale	SLE	Saint George Respiratory Questionnaire	WHO	World Health Organisation
			Systemic lupus erythematosus	WRES	Weight residue
		SLT	Speech and language therapy	WT1	Wilms' tumor